This study is not yet accepting patients
Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP
Summary
- Eligibility
- for people ages 12 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Bruce Wang, MD
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Bruce Wang, MD
My lab studies how the different cell types in the liver, in particular the hepatocyte, are generated during development, patterned and maintained during adulthood, and regenerate after injury. Our long-term goals are to improve the understanding of liver disease pathophysiology and develop novel methods of treatment for liver diseases, including cell replacement therapy.
Details
- Status
- not yet accepting patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Disc Medicine, Inc
- ID
- NCT05883748
- Phase
- Phase 2/3 Erythropoietic Protoporphyria Research Study
- Study Type
- Interventional
- Participants
- Expecting 200 study participants
- Last Updated